Accessing tyrosine kinase inhibitors (TKIs) for Chronic Myeloid Leukemia (CML) varies across Canadian provinces. Below is a step-by-step guide for patients in Saskatchewan.
Saskatchewan:
Consultation: Schedule an appointment with your healthcare provider to discuss TKI therapy.Prescription: After determining the appropriate TKI, your doctor will provide a prescription.
Coverage: The Saskatchewan Cancer Agency may cover specific TKIs under the Exception Drug Status program. Confirm the coverage details for your medication.
Application: Your physician will apply for EDS approval if necessary.
Approval: Once approved, you can access the medication through authorized pharmacies.
Drugs approved for treatment of CML at the Saskatchewan Cancer Agency:
Scemblix (Ascinimib), Bosulif (Bosutinib), Sprycel (Dasatinib), Gleevec (Imatinib), Tasigna (Nilotinib), Iclusig (Ponatinib).
Accessing tyrosine kinase inhibitors (TKIs) for Chronic Myeloid Leukemia (CML) varies across Canadian provinces. Below is a step-by-step guide for patients in Saskatchewan.
Saskatchewan
Consultation: Schedule an appointment with your healthcare provider to discuss TKI therapy.
Prescription: After determining the appropriate TKI, your doctor will provide a prescription.
Coverage: The Saskatchewan Cancer Agency may cover specific TKIs under the Exception Drug Status program. Confirm the coverage details for your medication.
Application: Your physician will apply for EDS approval if necessary.
Approval: Once approved, you can access the medication through authorized pharmacies.
Drugs approved for treatment of CML at the Saskatchewan Cancer Agency:
Scemblix (Ascinimib), Bosulif (Bosutinib), Sprycel (Dasatinib), Gleevec (Imatinib), Tasigna (Nilotinib), Iclusig (Ponatinib).
